Dr. Reddy's Laboratories Limited (RDDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.91 Billion ≈ $12.75 Billion USD) by net assets (€375.76 Billion ≈ $439.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Dr. Reddy's Laboratories Limited for the company's overall valuation and market capitalisation.
Dr. Reddy's Laboratories Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dr. Reddy's Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their cash flow conversion efficiency. Explore RDDA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
0.157x |
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
0.029x |
|
Companhia Paranaense de Energia - COPEL
SA:CPLE3
|
0.023x |
|
Repligen Corporation
NASDAQ:RGEN
|
0.016x |
|
Addtech AB (publ.)
ST:ADDT-B
|
0.106x |
|
CareTrust REIT Inc.
NYSE:CTRE
|
0.022x |
|
Pentair plc
STU:PNT
|
0.153x |
|
Zhengzhou Yutong Bus Co Ltd
SHG:600066
|
0.006x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy's Laboratories Limited from 2017 to 2025. View RDDA share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €337.17 Billion ≈ $394.18 Billion |
€46.43 Billion ≈ $54.28 Billion |
0.138x | -14.97% |
| 2024-03-31 | €280.55 Billion ≈ $327.99 Billion |
€45.43 Billion ≈ $53.12 Billion |
0.162x | -35.95% |
| 2023-03-31 | €232.86 Billion ≈ $272.24 Billion |
€58.88 Billion ≈ $68.83 Billion |
0.253x | +71.38% |
| 2022-03-31 | €190.53 Billion ≈ $222.75 Billion |
€28.11 Billion ≈ $32.86 Billion |
0.148x | -27.70% |
| 2021-03-31 | €174.98 Billion ≈ $204.57 Billion |
€35.70 Billion ≈ $41.74 Billion |
0.204x | +5.97% |
| 2020-03-31 | €154.99 Billion ≈ $181.20 Billion |
€29.84 Billion ≈ $34.89 Billion |
0.193x | -5.96% |
| 2019-03-31 | €140.20 Billion ≈ $163.91 Billion |
€28.70 Billion ≈ $33.56 Billion |
0.205x | +43.61% |
| 2018-03-31 | €126.46 Billion ≈ $147.85 Billion |
€18.03 Billion ≈ $21.08 Billion |
0.143x | -17.80% |
| 2017-03-31 | €124.04 Billion ≈ $145.02 Billion |
€21.51 Billion ≈ $25.15 Billion |
0.173x | -- |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more